- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03309423
Is Venous to Arterial Conversion (v-TAC) of Blood Gas Reliable in Critical Ill Patients in the ICU?
Utility of Mathematically Converted Venous to Arterial Blood Gas for Clinical Monitoring
Objective: Arterial blood gas (ABG) is essential in the clinical assessment of potential acutely ill patients venous to arterial conversion (v-TAC), a mathematical method, has recently been developed to convert peripheral venous blood gas (VBG) values to arterialized VBG (aVBG) values. The aim of this study is to test the reliability of aVBG compared to ABG in an intensive care unit (ICU) setting.
Method: Consecutive patients admitted to the ICU with pH values <7,35 or >7,45 are included in this study. Paired ABG and aVBG samples are drawn from patients via arterial catheter, central venous catheter and/or peripheral venous catheter and compared.
Study Overview
Status
Intervention / Treatment
Detailed Description
Arterial blood gas (ABG) analysis is essential in assessment of respiratory and metabolic status in acutely ill patients. In comparison to peripheral venous blood (PVG) sampling, the ABG sampling procedure is more painful for the patient and technically more challenging for the clinician to perform. Other drawbacks of ABG sampling include adverse events such as subcutaneous hematoma, arterial thrombosis or embolization, and pseudoaneurysms.
Peripheral venous blood gas (VBG) sampling has been suggested as an alternative to the ABG procedure. This procedure causes less patient discomfort and the sample can be analysed in combination with other venous blood tests. Studies have revealed that pH and bicarbonate have good correlation, whereas venous and arterial blood gasses (pO2 and pCO2) show low agreement.
However, a new method has been developed to calculate ABG values mathematically from peripheral venous blood by use of venous to arterial conversion (v-TAC) software (Obimedical, Denmark), supplemented with oxygen saturation measured by pulse oximetry. The principle of the method is a mathematical transformation of VBG values to arterialized values (aVBG) by simulating the transport of blood back through the tissue. Initial testing of the method in an emergency department setting showed acceptable clinical congruence between arterial and mathematically arterialized pH and pCO2 with a small difference (+/- SD) on 0.001 +/- 0.024 and 0.00 0.46 kPa, respectively. However, inaccurate values of pO2 were seen when oxygen saturation measured by pulse oximetry was above 96%, due to the flat shape of the oxygen dissociation curve (ODC).
Although most patients in the ICU have arterial catheters therefrom ABG can be drawn, applying arterial catheter is difficult or even impossible in some patients. In relation to step-down some patients get arterial catheters removed and in the event of deterioration in patients acid-base or respiratory disease aVBG could prove useful as a minimally invasive tool to assess patients status.
The aim of this study is to investigate if v-TAC is reliable and safe to use in patients with critically respiratory or metabolic disease admitted to the ICU.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Mads Lumholdt
- Phone Number: +45 51914156
- Email: m.lumholdt@rn.dk
Study Contact Backup
- Name: Kjeld Damgaard
- Phone Number: +45 51914156
- Email: kad@rn.dk
Study Locations
-
-
North Denmark
-
Aalborg, North Denmark, Denmark, 9000
- Recruiting
- Faculty of Medicine, Doctoral School, Ph.d. study
-
Contact:
- Christina Elmer, Secretary
- Email: doctoral.school@adm.aau.dk
-
Principal Investigator:
- Mads Lumholdt, Cand. Med.
-
Principal Investigator:
- Kjeld Damgaard, Cand. Med. Ph.d.
-
Sub-Investigator:
- Erika Christensen, Cand. Med. Professor
-
Sub-Investigator:
- Peter Leutscher, Cand. Med. Professor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients admitted to the intensive care with the following:
- Arterial catheter for other purpose.
- Peripheral venous catheter or central venous catheter for other purpose.
Exclusion Criteria:
- Normal pH in arterial blood gas.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Respiratory disease
Patients with acute respiratory insufficiency admitted to the ICU and with pH <7,35 or >7,45
|
Venous to arterial conversion (v-TAC) is a software (Obimedical, Denmark), which can convert venous blood gas values to arterial blood gas values.
The principle of the method is a mathematical transformation of VBG values to arterialized values (aVBG) by simulating the transport of blood back through the tissue.
To facilitate this simulation the following physiologically relevant assumptions were made: 1) The peripheral extremity was well perfused; 2) change in base excess across the tissue sampling site was approximately zero; 3) the respiratory quotient (rate of CO2 production and O2 utilisation over capillaries) could not vary outside the range 0.7 and 1.0, and 4) the haemoglobin concentration was constant from artery to vein.
|
Metabolic disease
Patients with acute metabolic disease admitted to the ICU and with pH <7,35 or >7,45
|
Venous to arterial conversion (v-TAC) is a software (Obimedical, Denmark), which can convert venous blood gas values to arterial blood gas values.
The principle of the method is a mathematical transformation of VBG values to arterialized values (aVBG) by simulating the transport of blood back through the tissue.
To facilitate this simulation the following physiologically relevant assumptions were made: 1) The peripheral extremity was well perfused; 2) change in base excess across the tissue sampling site was approximately zero; 3) the respiratory quotient (rate of CO2 production and O2 utilisation over capillaries) could not vary outside the range 0.7 and 1.0, and 4) the haemoglobin concentration was constant from artery to vein.
|
Sepsis
Patients with acute sepsis admitted to the ICU and with pH <7,35 or >7,45
|
Venous to arterial conversion (v-TAC) is a software (Obimedical, Denmark), which can convert venous blood gas values to arterial blood gas values.
The principle of the method is a mathematical transformation of VBG values to arterialized values (aVBG) by simulating the transport of blood back through the tissue.
To facilitate this simulation the following physiologically relevant assumptions were made: 1) The peripheral extremity was well perfused; 2) change in base excess across the tissue sampling site was approximately zero; 3) the respiratory quotient (rate of CO2 production and O2 utilisation over capillaries) could not vary outside the range 0.7 and 1.0, and 4) the haemoglobin concentration was constant from artery to vein.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lin's Concordance correlation coefficient (CCC)
Time Frame: 1. january 2018
|
Comparison of pH between ABG and aVBG (from peripheral venous catheter).
The closer CCC is to 1 the better correlation.
|
1. january 2018
|
Lin's Concordance correlation coefficient (CCC)
Time Frame: 1. january 2018
|
Comparison of pCO2 (Unit of Measurement: kilopascal) between ABG and aVBG (from peripheral venous catheter).
The closer CCC is to 1 the better correlation.
|
1. january 2018
|
Lin's Concordance correlation coefficient (CCC)
Time Frame: 1. january 2018
|
Comparison of pO2 (Unit of Measurement: kilopascal) between ABG and aVBG (from peripheral venous catheter).
The closer CCC is to 1 the better correlation.
|
1. january 2018
|
Lin's Concordance correlation coefficient (CCC)
Time Frame: 1. january 2018
|
Comparison of pH between ABG and aVBG (from central venous catheter).
The closer CCC is to 1 the better correlation.
|
1. january 2018
|
Lin's Concordance correlation coefficient (CCC)
Time Frame: 1. january 2018
|
Comparison of pCO2 (Unit of Measurement: kilopascal) between ABG and aVBG (from central venous catheter).
The closer CCC is to 1 the better correlation.
|
1. january 2018
|
Lin's Concordance correlation coefficient (CCC)
Time Frame: 1. january 2018
|
Comparison of pO2 (Unit of Measurement: kilopascal) between ABG and aVBG (from central venous catheter).
The closer CCC is to 1 the better correlation.
|
1. january 2018
|
Bland and Altman's plot
Time Frame: 1. january 2018
|
Mean difference and 95% limits-of-agreement of pH between ABG and aVBG (from peripheral venous catheter)
|
1. january 2018
|
Bland and Altman's plot
Time Frame: 1. january 2018
|
Mean difference and 95% limits-of-agreement of pCO2 (Unit of Measurement: kilopascal) between ABG and aVBG (from peripheral venous catheter).
|
1. january 2018
|
Bland and Altman's plot
Time Frame: 1. january 2018
|
Mean difference and 95% limits-of-agreement of pO2 (Unit of Measurement: kilopascal) between ABG and aVBG (from peripheral venous catheter).
|
1. january 2018
|
Bland and Altman's plot
Time Frame: 1. january 2018
|
Mean difference and 95% limits-of-agreement of pH between ABG and aVBG (from central venous catheter).
|
1. january 2018
|
Bland and Altman's plot
Time Frame: 1. january 2018
|
Mean difference and 95% limits-of-agreement of pCO2 (Unit of Measurement: kilopascal) between ABG and aVBG (from central venous catheter).
|
1. january 2018
|
Bland and Altman's plot
Time Frame: 1. january 2018
|
Mean difference and 95% limits-of-agreement of pO2 (Unit of Measurement: kilopascal) between ABG and aVBG (from central venous catheter).
|
1. january 2018
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with sepsis group.
Time Frame: 1. january 2018
|
Number and percentage of patients in 'sepsis' group.
|
1. january 2018
|
Number of patient with metabolic disease
Time Frame: 1. january 2018
|
Number and percentage of patients in 'metabolic disease' group.
|
1. january 2018
|
Number of patient with acute respiratory insufficiency
Time Frame: 1. january 2018
|
Number and percentage of patients in 'respiratory disease group' group.
|
1. january 2018
|
Mean number of days until pH neutrality in sepsis group
Time Frame: 1. january 2018
|
Mean number of days until patients ABG pH was within the range 7.35-7.45 in 'sepsis' group.
|
1. january 2018
|
Mean number of days until pH neutrality in patients with metabolic disease.
Time Frame: 1. january 2018
|
Mean number of days until patients ABG pH was within the range 7.35-7.45 in 'metabolic disease' group.
|
1. january 2018
|
Mean number of days until pH neutrality in patients with respiratory disease.
Time Frame: 1. january 2018
|
Mean number of days until patients ABG pH was within the range 7.35-7.45 in 'respiratory disease' group.
|
1. january 2018
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Peter Leutscher, Professor, Center for Clinical Research
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- v-TAC-ICU
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sepsis
-
University of Kansas Medical CenterUniversity of KansasRecruitingSepsis | Septic Shock | Sepsis Syndrome | Sepsis, Severe | Sepsis Bacterial | Sepsis BacteremiaUnited States
-
Jip GroenInBiomeRecruitingMicrobial Colonization | Neonatal Infection | Neonatal Sepsis, Early-Onset | Microbial Disease | Clinical Sepsis | Culture Negative Neonatal Sepsis | Neonatal Sepsis, Late-Onset | Culture Positive Neonatal SepsisNetherlands
-
Karolinska InstitutetÖrebro University, SwedenCompletedSepsis | Sepsis Syndrome | Sepsis, SevereSweden
-
The University of QueenslandRoyal Brisbane and Women's HospitalUnknown
-
Ohio State UniversityCompletedSepsis, Severe Sepsis and Septic ShockUnited States
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityRecruitingSevere Sepsis | Severe Sepsis Without Septic ShockUnited States
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsCompletedSepsis | Septic Shock | Severe Sepsis | Sepsis SyndromeUnited Kingdom
-
Zagazig UniversityRecruitingSepsis-associated EncephalopathyEgypt
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Presbyterian Hospital and other collaboratorsCompletedSepsis | Septic Shock | Severe Sepsis | Infection | Sepsis SyndromeUnited States
Clinical Trials on venous to arterial conversion (v-TAC)
-
Aalborg UniversityDepartment of Anesthesiology, North Denmark Regional Hospital; Center for Clinical...CompletedEmergency Service, Hospital | Matched-Pair Analysis | Blood Gas Analysis
-
Centre Hospitalier Universitaire DijonCompletedHyperlactatemia | Actue Circulatory FailureFrance
-
Wake Forest University Health SciencesCompletedIdiopathic Intracranial HypertensionUnited States
-
Philips RespironicsTerminated
-
University of California, IrvineWithdrawnAnesthetized Healthy Patients (ASA 1 or 2) in the Supine Position, Excluding Head, Neck and Head Surgeries | Anesthetized Patient With Severe Systemic Disease (ASA 3 or 4)United States
-
Julio RamirezUniversity of LouisvilleTerminatedOsteomyelitisUnited States